Mather Group’s Axsome Therapeutics AXSM Stock Holding History

Mather Group’s Portfolio AXSM Stock Details AXSM Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q3	$3.87K	Buy	+21	New	+$4.57K	﹤0.01%	1868

Other funds holding AXSM

Assenagon Asset Management Senningerberg, Luxembourg $103B AUM 40.17% 1-Year Est. Return

IFP Advisors Tampa, Florida $5.86B AUM 20.09% 1-Year Est. Return

HB Wealth Management Atlanta, Georgia $19.5B AUM 16.96% 1-Year Est. Return

Iridian Asset Management Westport, Connecticut $275M AUM 37.66% 1-Year Est. Return

Baldwin Wealth Partners Marion, Massachusetts $1.52B AUM 21.45% 1-Year Est. Return

Washington Trust Advisors Wellesley, Massachusetts $1.4B AUM 26.88% 1-Year Est. Return

Mutual of America Capital Management New York $10.1B AUM 33.74% 1-Year Est. Return

Wealth Enhancement Advisory Services Plymouth, Minnesota $67.3B AUM 21.9% 1-Year Est. Return

Stanley-Laman Group Berwyn, Pennsylvania $915M AUM 50.26% 1-Year Est. Return

Hennion & Walsh Asset Management Parsippany, New Jersey $3.42B AUM 25.82% 1-Year Est. Return

Mather Group's AXSM Position: Q3 2026 in Review

Mather Group opened a new position in Axsome Therapeutics (AXSM) in Q3 2026: 21 shares worth $3.87K. The stake represents ﹤0.01% of the portfolio and ranks #1868 among its holdings.

63 funds tracked by Wall St. Rank hold AXSM as of Q3 2026.

Mather Group held 21 shares of Axsome Therapeutics worth $3.87K as of Q3 2026.
Axsome Therapeutics was a new Mather Group position in Q3 2026.
Axsome Therapeutics made up ﹤0.01% of Mather Group's portfolio in Q3 2026, its #1868 holding.
63 funds tracked by Wall St. Rank held Axsome Therapeutics as of Q3 2026.

Based on Mather Group's 13F filing for Q3 2026, filed 14 Oct 2026.